Does anyone know what the SOLiD 3plus upgrade entails?
-
-
<Original post Deleted since we haven't been through the 3+ upgrade yet>.
Notes from my co-worker (who was out at the recent SOLiD meeting): Not much of machine change this time, just a lower-profile flowcell. He also reports a 50% increase in beads per flowcell and that v.3 chemistry will run on the v.3.5 machines. -
This was discussed at length at the SOLiD User's summit last week. With respect to what Rick wrote, a new bead finding algorithm will allow a roughly 50% increase in the number of beads per flowcell. The recommended bead density will increase from 130-150 thousand beads/panel to 220 thousand beads/panel. Or from roughly 330 million raw reads/slide to 500 million.Originally posted by NextGenSeq View Post
This is accompanies a flowcell swap out, new slide carriers and a newly optimized sequence master mix. I remember there being a slight decrease in chemistry cost, although my guess is that it is more than counteracted by the extra ePCR that will be necessary to generate all those beads...
Perhaps more importantly a major secondary/tertiary software release will happen in "early November" called "BioScope v 1.0". Briefly, this package will replace Global SETS, but be free for SOLiD owners (unlike Global SETS). Mapping is said to be 3-10x faster and utilize a "seeded extension mapping" method that is said to successfully map 10-30% more reads.
The really crazy stuff seems to be in version 4, which is slated for "2010".
--
PhillipComment
-
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...10-14-2026, 09:55 AM -
Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.
We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing...
Comment